BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007;24:137-46. [PMID: 17848736 DOI: 10.1007/BF02698032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Kang BW, Kim JG, Kwon OK, Chung HY, Yu W. Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol 2014; 20(18): 5396-5402 [PMID: 24833869 DOI: 10.3748/wjg.v20.i18.5396] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, Berglund A, Glimelius B, Lind PA; Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010;13:155-61. [PMID: 20820984 DOI: 10.1007/s10120-010-0553-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
3 Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs. 2014;32:542-548. [PMID: 24526575 DOI: 10.1007/s10637-014-0070-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
4 Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol 2015;8:189-205. [PMID: 26136837 DOI: 10.1177/1756283X15585468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Farhat FS, Kattan J, Chahine GY, Younes FC, Nasr FL, Mroue RM, Ghosn MG. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer. Med Oncol. 2010;27:722-727. [PMID: 19644778 DOI: 10.1007/s12032-009-9275-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, Xie L, Zou Z, Qian X, Ding Y, Guan W, Liu B. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. J Transl Med 2013;11:73. [PMID: 23517622 DOI: 10.1186/1479-5876-11-73] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
7 Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. Br J Cancer. 2011;105:1522-1532. [PMID: 21997136 DOI: 10.1038/bjc.2011.397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
8 Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle 2017;16:1193-200. [PMID: 28486050 DOI: 10.1080/15384101.2017.1320005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
9 Fakhruddin N, Bahmad HF, Aridi T, Yammine Y, Mahfouz R, Boulos F, Awada A, Farhat F. Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature. Front Med (Lausanne) 2017;4:164. [PMID: 29034239 DOI: 10.3389/fmed.2017.00164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Wang L, Xie L, Wang J, Shen J, Liu B. Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer. BMC Gastroenterol. 2013;13:173. [PMID: 24359226 DOI: 10.1186/1471-230x-13-173] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Koucky K, Wein A, Konturek PC, Albrecht H, Reulbach U, Männlein G, Wolff K, Ostermeier N, Busse D, Golcher H, Schildberg C, Janka R, Hohenberger W, Hahn EG, Siebler J, Neurath MF, Boxberger F. Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing. Med Sci Monit 2011;17:CR248-58. [PMID: 21525806 DOI: 10.12659/msm.881764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Yashiro M, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer. 2013;109:2619-2628. [PMID: 24129235 DOI: 10.1038/bjc.2013.638] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
13 Kimura M, Usami E, Kanematsu T, Iwai M, Yoshimura T, Mori H, Sugiyama T, Teramachi H. Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer. Mol Clin Oncol 2014;2:466-72. [PMID: 24772319 DOI: 10.3892/mco.2014.260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]